ACROBiosystems Aneuro Collaborates With Diagnostic Biochips To Accelerate Neuroscience Drug Discovery

ACROBiosystems recently announced the launch of in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips via ACRO Certify and its Aneuro brand. Two companies have agreed to work together to accelerate neurological drug discovery and commercialization. Electrophysiology is an essential component of neuroscience research, particularly when attempting to understand the neural network.

Monitoring the brain's field potential and electrical signals at the neuronal level across different brain regions can provide critical information for understanding neural network function and the biological pathway underlying neurological disease pathology. However, due to the inherent complexity of the neural network, in vivo electrophysiology is difficult. This includes not only data collection, but also consideration for the in vivo animal model, which is primarily rodent in nature.

The probes available are designed to function without a headstage, reducing the physical burden on the animal heads while not compensating in signal channels. Deep-array electrodes with a recording depth of 90mm and 128 channels are also available. Data acquisition systems, as well as AI / Cloud-based data analysis software, are available to drive structural and functional analysis of neural circuits, electrophysiological biomarker discovery, and drug screening in addition to probes. Beginner's guides and trainings are available for those looking to begin their first foray into the neurosciences.

ACROBiosystems Group is a biotechnology firm that aims to be a cornerstone of the global biopharmaceutical and health industries by developing innovative products and business models. Diagnostic Biochips, Inc (DBC) is a US-based biosensor platform technology firm that is redefining measurement in medicine. DBC has developed a proprietary sensor "functionalization" process and a suite of biosensors that are set to transform the medical monitoring process. Its paradigm-shifting sensors are a cost-effective method for the direct and continuous monitoring of medically important compounds, such as drugs and biomarkers.